CA2885240A1 - Novel mva virus and uses thereof - Google Patents
Novel mva virus and uses thereof Download PDFInfo
- Publication number
- CA2885240A1 CA2885240A1 CA2885240A CA2885240A CA2885240A1 CA 2885240 A1 CA2885240 A1 CA 2885240A1 CA 2885240 A CA2885240 A CA 2885240A CA 2885240 A CA2885240 A CA 2885240A CA 2885240 A1 CA2885240 A1 CA 2885240A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- gene product
- virus
- cell
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 240
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims abstract description 236
- 229960005486 vaccine Drugs 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 39
- 238000004519 manufacturing process Methods 0.000 claims abstract description 32
- 238000012258 culturing Methods 0.000 claims abstract description 28
- 206010046865 Vaccinia virus infection Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000007089 vaccinia Diseases 0.000 claims abstract description 11
- 239000003085 diluting agent Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 430
- 239000000047 product Substances 0.000 claims description 279
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 238
- 150000001413 amino acids Chemical class 0.000 claims description 180
- 108090000623 proteins and genes Proteins 0.000 claims description 149
- 230000004048 modification Effects 0.000 claims description 144
- 238000012986 modification Methods 0.000 claims description 144
- 150000007523 nucleic acids Chemical group 0.000 claims description 143
- 101150085281 A3L gene Proteins 0.000 claims description 140
- 101150096528 A9L gene Proteins 0.000 claims description 134
- 101150049392 A34R gene Proteins 0.000 claims description 132
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 128
- 230000035772 mutation Effects 0.000 claims description 96
- 150000001875 compounds Chemical class 0.000 claims description 59
- 239000002609 medium Substances 0.000 claims description 38
- 238000012217 deletion Methods 0.000 claims description 35
- 230000037430 deletion Effects 0.000 claims description 35
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 241000271566 Aves Species 0.000 claims description 34
- 101100350652 Vaccinia virus (strain Western Reserve) VACWR122 gene Proteins 0.000 claims description 34
- 230000001464 adherent effect Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 230000010076 replication Effects 0.000 claims description 28
- 101150115056 A31R gene Proteins 0.000 claims description 25
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 20
- 102220005376 rs33915947 Human genes 0.000 claims description 19
- 230000004663 cell proliferation Effects 0.000 claims description 18
- 239000013587 production medium Substances 0.000 claims description 18
- 102200026258 rs28929484 Human genes 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 238000002255 vaccination Methods 0.000 claims description 15
- 102220311820 rs1376867262 Human genes 0.000 claims description 14
- 241000288906 Primates Species 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 239000013592 cell lysate Substances 0.000 claims description 4
- 102220179791 rs752964419 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 description 55
- 241000272525 Anas platyrhynchos Species 0.000 description 36
- 230000002458 infectious effect Effects 0.000 description 34
- 238000004113 cell culture Methods 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 241000287828 Gallus gallus Species 0.000 description 25
- 230000002238 attenuated effect Effects 0.000 description 24
- 101100489783 Vaccinia virus (strain Ankara) MVA120L gene Proteins 0.000 description 23
- 101100489785 Vaccinia virus (strain Western Reserve) VACWR128 gene Proteins 0.000 description 23
- 238000004114 suspension culture Methods 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 241000725303 Human immunodeficiency virus Species 0.000 description 18
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000006229 amino acid addition Effects 0.000 description 16
- 238000002955 isolation Methods 0.000 description 15
- 241000272814 Anser sp. Species 0.000 description 14
- 241000286209 Phasianidae Species 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 11
- 239000006166 lysate Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 210000002023 somite Anatomy 0.000 description 10
- 241000711950 Filoviridae Species 0.000 description 9
- 241000710831 Flavivirus Species 0.000 description 9
- 241000711549 Hepacivirus C Species 0.000 description 9
- 241000150452 Orthohantavirus Species 0.000 description 9
- 241000700618 Vaccinia virus Species 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000272834 Cairina moschata Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229960000074 biopharmaceutical Drugs 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- 229920000936 Agarose Polymers 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004115 adherent culture Methods 0.000 description 6
- 230000031018 biological processes and functions Effects 0.000 description 6
- 108091092356 cellular DNA Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 101150029707 ERBB2 gene Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010008707 Mucin-1 Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000289054 Rousettus aegyptiacus Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 108010015780 Viral Core Proteins Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003927 comet assay Methods 0.000 description 3
- 231100000170 comet assay Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000013383 initial experiment Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001364432 Microbates Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000012863 analytical testing Methods 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000191985 Anas superciliosa Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 238000005773 Enders reaction Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241000941424 Hermitage virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000883510 Kolla Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101100269369 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AGE1 gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 229940124928 YF-Vax Drugs 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2885240A1 true CA2885240A1 (en) | 2014-04-03 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2885240A Abandoned CA2885240A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (enExample) |
| EP (1) | EP2900810B1 (enExample) |
| JP (1) | JP2015535687A (enExample) |
| CN (1) | CN104812894B (enExample) |
| AU (1) | AU2012391162A1 (enExample) |
| BR (1) | BR112015006798A2 (enExample) |
| CA (1) | CA2885240A1 (enExample) |
| DK (1) | DK2900810T3 (enExample) |
| IN (1) | IN2015DN02335A (enExample) |
| MX (1) | MX2015003687A (enExample) |
| RU (1) | RU2015115898A (enExample) |
| WO (1) | WO2014048500A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11104884B2 (en) | 2017-02-23 | 2021-08-31 | Probiogen Ab | Vaccinia virus vectors related to MVA with extensive genomic symmetries |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| CN112384615A (zh) | 2018-07-04 | 2021-02-19 | 普罗拜奥根股份公司 | 用于纯化包膜病毒的方法 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| WO2005048957A2 (en) | 2003-02-20 | 2005-06-02 | Therion Biologics Corporation | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2900810T3 (en) | 2019-04-29 |
| IN2015DN02335A (enExample) | 2015-08-28 |
| CN104812894A (zh) | 2015-07-29 |
| WO2014048500A1 (en) | 2014-04-03 |
| US9732325B2 (en) | 2017-08-15 |
| MX2015003687A (es) | 2015-06-15 |
| JP2015535687A (ja) | 2015-12-17 |
| BR112015006798A2 (pt) | 2017-11-21 |
| RU2015115898A (ru) | 2016-11-20 |
| EP2900810A1 (en) | 2015-08-05 |
| EP2900810B1 (en) | 2019-02-20 |
| CN104812894B (zh) | 2021-10-22 |
| US20150299666A1 (en) | 2015-10-22 |
| AU2012391162A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9732325B2 (en) | MVA virus and uses thereof | |
| JP5783642B2 (ja) | Ｍｖａの主なゲノム欠失を含むワクシニアウイルス変異体 | |
| TW575664B (en) | Recombinant MVA virus, and the use thereof | |
| MX2008015166A (es) | Proceso para producir poxvirus y composiciones de poxvirus. | |
| KR20130030298A (ko) | 불멸화 조류 세포주들 | |
| BRPI0215003B1 (pt) | método para a recuperação e purificação de poxvírus a partir de células infectadas | |
| CN103088049A (zh) | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 | |
| Jordan et al. | A chemically defined production process for highly attenuated poxviruses | |
| Léon et al. | The EB66® cell line as a valuable cell substrate for MVA-based vaccines production | |
| US11104884B2 (en) | Vaccinia virus vectors related to MVA with extensive genomic symmetries | |
| US11999975B2 (en) | Method for purifying an enveloped virus | |
| Melamed et al. | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants | |
| US20060216312A1 (en) | Mutants of replication competent vaccinia virus | |
| JP2006509526A (ja) | トリ胚性幹細胞上におけるａｌｖａｃの産生 | |
| KR20250156704A (ko) | 메추라기 세포 배양을 통한 폭스바이러스 생산 | |
| WO2024188801A1 (en) | Use of quail cell lines for poxvirus production | |
| AU2024280931A9 (en) | Rapid selection system for the generation of recombinant enveloped viruses | |
| AU2024280931A1 (en) | Rapid selection system for the generation of recombinant enveloped viruses | |
| WO2024245721A1 (en) | Diploid recombinant nucleocytoplasmic large dna viral vectors | |
| Ricci | Generation of modified vaccinia virus ankara recombinants by rescue of the essential D4R gene | |
| EP2199385A1 (en) | Specific and persistent activation of heat shock response in cell lines using a viral factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180928 |